<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646837</url>
  </required_header>
  <id_info>
    <org_study_id>2020-IMFINZI-001</org_study_id>
    <nct_id>NCT04646837</nct_id>
  </id_info>
  <brief_title>Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models</brief_title>
  <official_title>Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center prospective exploratory single-arm neoadjuvant therapy study, based on a&#xD;
      prospective cohort study, according to patients' blood and tumor samples before and after&#xD;
      neoadjuvant treatment, WES, GEP gene expression profiling, TCR sequencing and ctDNA dynamic&#xD;
      monitoring were used to explore the intratumoral immune consequences of PD-1 monoclonal&#xD;
      antibody administration and identify potential Response biomarker.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the safety and immunobiological effects of 2 cycles of duvalumab combined with&#xD;
      albumin paclitaxel + cisplatin/carboplatin for patients with stage IB-IIIA non-small cell&#xD;
      lung cancer; use whole exome sequencing , GEP gene expression profile detection based on&#xD;
      NanoString platform and other methods to predict the efficacy of IMFINZI neoadjuvant therapy,&#xD;
      looking for potential biomarkers; study the impact of neoadjuvant therapy of I drug on the&#xD;
      tumor microenvironment at multiple levels such as genome, transcriptome, PD-1/PD-L1 protein&#xD;
      transcription and expression, T cell TCR immune groupthe library and T cell subsets, and&#xD;
      provide comprehensive exploratory research evidence for finding the biomarker for the&#xD;
      neoadjuvant anti-PD-L1 therapy of lung cancer .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MPR</measure>
    <time_frame>At the date of tumor assessment after surgery, estimated at approximately 24 weeks post-baseline</time_frame>
    <description>Major pathologic response is defined as the presence of 10% or less of vital tumor cells in the sections of the primary lesion and/or mediastinal lymph nodes presenting focal microscopic disease after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at 24 months from the first dose of neadjuvant treatment</time_frame>
    <description>The progression free survival is the time until the patients disease progresses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 3 years from the first dose of neoadjuvant treatment</time_frame>
    <description>Time when the patient is still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>from the first dose of neoadjuvant treatment until 90 days after the last dose of adjuvant treatment</time_frame>
    <description>Toxicities caused by the drug during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 1000 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IB-IIIA NSCLC adult patients followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 15000mg Q4W for 8 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>IMFINZI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin Paclitaxel</intervention_name>
    <description>Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin/Cisplatin</intervention_name>
    <description>Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/„é° for 2 cycle</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years old&#xD;
&#xD;
          -  Male or female (no fertility requirement)&#xD;
&#xD;
          -  Meet NCCN lung cancer diagnostic criteria&#xD;
&#xD;
          -  No radical mastectomy, radiotherapy, chemotherapy, targeted therapy and immunotherapy&#xD;
&#xD;
          -  Resectable stage Ib-IIIa non-small cell lung cancer (NSCLC) patients confirmed by&#xD;
             imaging and biopsy; clear lung histopathological sample results have been obtained&#xD;
             during screening, and all molecular biological tests can be completed.&#xD;
&#xD;
          -  Patients without serious comorbidities, including but not limited to basic&#xD;
             cardiovascular and cerebrovascular diseases, and patients whose clinical conditions&#xD;
             allow to tolerate thoracic surgery&#xD;
&#xD;
          -  Female and male subjects of childbearing age must use appropriate contraceptive&#xD;
             measures during the study period and 6 months after the last study medication. Female&#xD;
             subjects of childbearing age must have a negative pregnancy test&#xD;
&#xD;
          -  Pathologically confirmed as lung adenocarcinoma or squamous cell carcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unstable vital signs, need vasoactive drugs, or need intensive care unit&#xD;
             (ICU) support&#xD;
&#xD;
          -  Patients with active infections (including infections such as bacteria, fungi,&#xD;
             viruses, tuberculosis, and various types of hepatitis) within 3 months before the&#xD;
             first study medication&#xD;
&#xD;
          -  Symptoms and signs of severe or uncontrolled liver, kidney, gastrointestinal,&#xD;
             endocrine, lung, heart, neuropsychiatric, or brain disease&#xD;
&#xD;
          -  Patients with a history of autoimmune diseases (inflammation or insufficiency of&#xD;
             glands such as thyroid, pituitary, adrenal gland, etc., immunological diseases with&#xD;
             positive autoantibodies)&#xD;
&#xD;
          -  Is participating in other drug trials&#xD;
&#xD;
          -  One month before the enrollment plan to receive immunotherapy, he had used any&#xD;
             anti-systemic antibiotic therapy, hormone therapy, immunosuppressive therapy, etc.&#xD;
&#xD;
          -  The pathology is small cell lung cancer or other neuroendocrine tumors or sarcomas,&#xD;
             rare tumors or lung adenocarcinoma/squamous cell carcinoma containing the above&#xD;
             components.&#xD;
&#xD;
          -  The patient has a history of malignant tumors other than lung cancer&#xD;
&#xD;
          -  Patients with sensitive gene mutations in EGFR (E19del/E21 L858R) and ALK (various&#xD;
             types of fusion mutations)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Naixin Liang, Doctor</last_name>
    <phone>+86 13701089919</phone>
    <email>pumchnelson@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naixin Liang, Doctor</last_name>
      <phone>13701089919</phone>
      <email>pumchnelson@163.com</email>
    </contact>
    <investigator>
      <last_name>Naixin Liang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shanqing Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant immunotherapy</keyword>
  <keyword>IMFINZI</keyword>
  <keyword>multiple-omics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

